Clinical trialNCT05879367RecruitingPhase 1Interventional

Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma

SponsorOrbus Therapeutics, Inc.Enrollment66AstrocytomaAstrocytoma, IDH-MutantGBMGlioblastomaGlioblastoma IDH (Isocitrate Dehydrogenase) WildtypeGlioblastoma Multiforme+1 more conditions

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to establish the recommended phase 2 dose of eflornithine in combination with temozolomide in patients whose glioblastoma or astrocytoma is newly diagnosed, and to evaluate safety and tolerability of this combination at that dose.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Howard Colman, MD, PhD
Huntsman Cancer Institute
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of Alabama at Birmingham
Birmingham, Alabama, United States
Withdrawn
Henry Ford Hospital
Detroit, Michigan, United States
Tobias Walbert, MD, PhD, MPH
Recruiting
Columbia University Medical Center - Herbert Irving Pavilion
New York, New York, United States
Maria Diaz, MD
Recruiting
Duke University
Durham, North Carolina, United States
Annick Desjardins, MD, FRCPC
Recruiting
the Cleveland Clinic
Cleveland, Ohio, United States
David Peereboom, MD
Recruiting
Brown University Health/rhode Island Hospital
Providence, Rhode Island, United States
Eric Wong, MD
Recruiting
Ut Md Anderson Cancer Center
Houston, Texas, United States
Carlos Kamiya Matsuoka, MD
Recruiting
University of Utah, Huntsman Cancer Institute
Salt Lake City, Utah, United States
Howard Colman, MD, PhD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

EflornithineTemozolomide →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 24 Jul 2023
Primary completion: 30 Jun 2026
Completion: 30 Jun 2026
Last update posted: 25 Jun 2025
Registered enrollment: 66
Registry id: NCT05879367

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.